The marked reduction in Mcl-1—an anti-apoptotic factor frequently associated with chemoresistance and poor prognosis in cancer patients [39]—suggests that TDB may also sensitize GBM cells to other therapeutic agents, further enhancing its potential as an effective treatment strategy. This evidence concerns the gene MCL1 and glioblastoma.